Literature DB >> 17023207

A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure.

Roy S Gardner1, Kwok S Chong, James J Morton, Theresa A McDonagh.   

Abstract

BACKGROUND: The prognosis of chronic heart failure has improved with modern medical therapy. However, identifying those patients who fail to respond to such therapy and therefore those who remain at high risk is notoriously difficult. The B-type natriuretic peptides are established independent predictors of prognosis in CHF. However, the relevance of a change in NT-proBNP concentration over time in advanced heart failure is unknown.
METHODS: We prospectively studied 133 patients with advanced CHF referred for consideration of cardiac transplantation. Plasma for NT-proBNP analysis was sampled at baseline and a median of 4 months later in the 112 patients surviving without cardiac transplantation. Patients were followed up for a median of 1003 days.
RESULTS: The primary endpoint of all-cause mortality occurred in 30 (26.8%) patients. Those subjects who had the highest NT-proBNP concentration at 4 months were at the greatest risk of death (log rank statistic=10.4, p=0.001). On Cox regression analysis, both a NT-proBNP concentration above the median and an absolute increase in NT-proBNP were independent predictors of mortality (chi(2)=53, p<0.0001 and chi(2)=17.3, p<0.0001, respectively).
CONCLUSION: A single NT-proBNP concentration above the median and a change in NT-proBNP concentration over a 4-month period were independent predictors of mortality in patients with advanced heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023207     DOI: 10.1016/j.ejheart.2006.07.002

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  6 in total

1.  Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure.

Authors:  Robb D Kociol; Steven E McNulty; Adrian F Hernandez; Kerry L Lee; Margaret M Redfield; Russell P Tracy; Eugene Braunwald; Christopher M O'Connor; G Michael Felker
Journal:  Circ Heart Fail       Date:  2012-12-18       Impact factor: 8.790

Review 2.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

Review 3.  Heart failure biomarkers.

Authors:  Rajiv Choudhary; Navaid Iqbal; Fatima Khusro; Erin Higginbotham; Erik Green; Alan Maisel
Journal:  J Cardiovasc Transl Res       Date:  2013-04-20       Impact factor: 4.132

4.  Expression of the vitamin d receptor is increased in the hypertrophic heart.

Authors:  Songcang Chen; Denis J Glenn; Wei Ni; Christopher L Grigsby; Keith Olsen; Minobu Nishimoto; Christopher S Law; David G Gardner
Journal:  Hypertension       Date:  2008-10-20       Impact factor: 10.190

5.  Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome.

Authors:  Marijke van der Meulen; Susanna den Boer; Gideon J du Marchie Sarvaas; Nico Blom; Arend D J Ten Harkel; Hans M P J Breur; Lukas A J Rammeloo; Ronald Tanke; Ad J J C Bogers; Willem A Helbing; Eric Boersma; Michiel Dalinghaus
Journal:  ESC Heart Fail       Date:  2021-02-05

6.  Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.

Authors:  Koichi Node; Teruo Inoue; Valentin Boyko; Ilan Goldberg; Enrique Z Fisman; Yehuda Adler; Ehud Schwammenthal; Zipora Matas; Solomon Behar; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-01-28       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.